A number of other analysts have also commented on PTLA. Oppenheimer reaffirmed a buy rating and issued a $80.00 target price on shares of Portola Pharmaceuticals in a research report on Wednesday, September 6th. Morgan Stanley reaffirmed an overweight rating and issued a $81.00 target price (up from $75.00) on shares of Portola Pharmaceuticals in a research report on Friday, October 6th. Goldman Sachs Group began coverage on Portola Pharmaceuticals in a research note on Friday, December 1st. They set a buy rating and a $75.00 price target for the company. BidaskClub downgraded Portola Pharmaceuticals from a sell rating to a strong sell rating in a research note on Thursday, December 7th. Finally, Citigroup reiterated a buy rating and set a $74.00 price target on shares of Portola Pharmaceuticals in a research note on Thursday, December 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $70.65.
Shares of Portola Pharmaceuticals (PTLA) traded down $0.57 during trading on Monday, reaching $48.84. The company had a trading volume of 650,400 shares, compared to its average volume of 1,156,400. Portola Pharmaceuticals has a twelve month low of $23.70 and a twelve month high of $67.10. The company has a market cap of $3,150.00, a price-to-earnings ratio of -11.31 and a beta of 1.21. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.31 and a quick ratio of 8.31.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) EPS for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.08. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The business had revenue of $3.83 million during the quarter, compared to analyst estimates of $4.71 million. During the same period in the previous year, the company posted ($1.64) EPS. The firm’s revenue was down 58.9% compared to the same quarter last year. sell-side analysts predict that Portola Pharmaceuticals will post -4.94 earnings per share for the current fiscal year.
In other Portola Pharmaceuticals news, Director Henry Ward Wolff sold 12,000 shares of Portola Pharmaceuticals stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $47.00, for a total transaction of $564,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 5.50% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Portola Pharmaceuticals by 0.9% in the 2nd quarter. BlackRock Inc. now owns 4,071,966 shares of the biopharmaceutical company’s stock worth $228,721,000 after buying an additional 37,241 shares during the last quarter. State Street Corp boosted its stake in shares of Portola Pharmaceuticals by 5.3% in the 2nd quarter. State Street Corp now owns 2,085,838 shares of the biopharmaceutical company’s stock worth $117,164,000 after buying an additional 105,207 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Portola Pharmaceuticals by 3.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 744,702 shares of the biopharmaceutical company’s stock worth $40,081,000 after buying an additional 26,544 shares during the last quarter. Kornitzer Capital Management Inc. KS boosted its stake in shares of Portola Pharmaceuticals by 38.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 727,812 shares of the biopharmaceutical company’s stock worth $39,324,000 after buying an additional 202,925 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Portola Pharmaceuticals by 17.2% in the 2nd quarter. Goldman Sachs Group Inc. now owns 688,092 shares of the biopharmaceutical company’s stock worth $38,650,000 after buying an additional 101,046 shares during the last quarter. Hedge funds and other institutional investors own 87.25% of the company’s stock.
WARNING: “Portola Pharmaceuticals (PTLA) Earns Buy Rating from William Blair” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://transcriptdaily.com/2018/01/05/portola-pharmaceuticals-ptla-earns-buy-rating-from-william-blair.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.